DSIP

Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke.

2021 · Preclinical

Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia.

2009 · European journal of anaesthesiology · Human evidence

Background and objective Delta sleep-inducing peptide (DSIP) is an endogenous peptide that crosses the blood-brain barrier, named after its association with natural sleep and enhanced electroencephalogram (EEG) delta rhythm. The objective of this study was to determine whether DSIP could be used as an adjunct to volatile anaesthesia in humans, our hypothesis being that DSIP is a natural hypnotic that would increase anaesthetic depth. The aims were to assess depth of anaesthesia using bispectral index (BIS), the EEG and heart rate variability (HRV), and to determine whether DSIP altered the symmetry of EEG between the left and right cerebral hemispheres. Methods Twenty-four female ASA I or II patients gave written, informed consent to a protocol approved by our local research ethics committee. Twelve were randomly assigned as controls to receive saline. The other 12 were randomly allocated to receive one of three intravenous bolus doses of DSIP (Clinalfa) at 25, 50 or 100 nmol kg(-1). The first administration of DSIP was while awake and the second after induction of anaesthesia with propofol and maintenance with isoflurane. BIS and EEG parameters were measured continuously using a bilateral electrode montage. Results DSIP significantly increased heart rate, decreased HRV and, paradoxically, significantly reduced delta rhythm along with reducing burst suppression and increasing BIS at 25 nmol kg(-1) during isoflurane anaesthesia. DSIP also significantly altered bilateral symmetry of EEG. Conclusion DSIP probably reduced parasympathetic tone and decreased (lightened) the depth of anaesthesia measured using BIS.

Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial.

1998 · Journal of clinical psychopharmacology · Human evidence

Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.

1992 · Neuropsychobiology · Human evidence

The influence of delta sleep-inducing peptide (DSIP) on sleep was studied in 16 chronic insomniac patients according to a double-blind matched-pairs parallel-groups design. Subjects slept for 5 consecutive nights in the laboratory. Night 1 was used for adaptation, night 2 for baseline measurements. In the afternoon before the 3rd, 4th and 5th night, half of the patients received intravenously 25 nmol/kg body weight DSIP, and half of the patients a glucose solution (placebo). Measures for sleep structure, objective (polysomnography) and subjective sleep quality and for subjective tiredness were assessed. The results for objective sleep quality indicated higher sleep efficiency and shorter sleep latency with DSIP as compared to placebo. One measure of subjectively estimated tiredness decreased within the DSIP group. Data analysis suggested, however, that the statistically significant effects were weak and in part could be due to an incidental change in the placebo group. As none of the other measures, including subjective sleep quality, showed any change, it was concluded that short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit.

Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.

1987 · European neurology · Human evidence

Impaired daytime functions are a significant part of chronic insomnia besides sleep disturbance. Therefore, the effects of intermediate-term delta-sleep-inducing peptide (DSIP) administration on sleep and daytime performance were investigated in 14 middle-aged chronic insomniacs. DSIP was administered under placebo-controlled, double-blind conditions for 7 successive nights. Polysomnograms were obtained for placebo baseline, beginning and end of DSIP treatment, and one placebo posttreatment night; daytime psychological state and mental performance were extensively tested before and after 6 DSIP injections. The treatment substantially improved night sleep with the first and additionally with repeated doses. These effects were maintained for the first posttreatment (placebo) night. Efficiency of night sleep and daytime rest reached the levels of normal controls. Alertness and performance at daytime increased significantly. The study demonstrates the efficacy of DSIP for the treatment of impaired sleep and daytime functions as well.